Zynerba Pharmaceuticals Stock Plunges on Failed THC Trial

Analyst ratings are firmly optimistic on the drug stock

Managing Editor
Jul 5, 2018 at 9:11 AM
facebook twitter linkedin

Shares of drug concern Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) have plunged in pre-market trading, after the company reported top line results for a Phase 1 trial of its ZYN001 tetrahydrocannabinol (THC) transdermal patch. While the drug was well tolerated, target blood levels were not achieved. ZYNE is down 21.9% at $7.51 ahead of the bell, on track to open at a new year-to-date low.

Zynerba Pharmaceuticals stock has been an underperformer on the charts since last year's mid-April peak near $26, having shed nearly 44% over the past 52 weeks. The stock's recent rally attempt was turned away by the $12.50 mark, which also coincides with its year-to-date breakeven level.

Despite the stock's underwhelming performance on the charts, analyst ratings are leaning optimistic. Currently, eight firms are covering the drug stock, with five sporting a "strong buy" recommendation. Further, ZYNE's average 12-month price target comes in at $17.50 -- representing a more than 80% premium to Tuesday's close.

Short interest fell 4% during the past two reporting periods, but ZYNE remains heavily shorted; these bearish bets account for 23% of the stock's total available float, or 12.4 times its average daily trading volume. However, given the magnitude of today's pre-market sell-off, Zynerba shares appear to be headed for the short-sale restricted list.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Schaeffer's Daily Bulletin Offer


Special Offers from Schaeffer's Trading Partners